Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning

被引:284
作者
Cai, SL
Tee, AR
Short, JD
Bergeron, JM
Kim, J
Shen, JJ
Guo, RF
Johnson, CL
Kiguchi, K
Walker, CL [1 ]
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Smithville, TX 78957 USA
[2] Univ Dundee, Inst Med Sci, Div Mol Physiol, Dundee DD1 5EH, Scotland
关键词
D O I
10.1083/jcb.200507119
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Loss of tuberin, the product of TSC2 gene, increases mammalian target of rapamycin ( mTOR) signaling, promoting cell growth and tumor development. However, in cells expressing tuberin, it is not known how repression of mTOR signaling is relieved to activate this pathway in response to growth factors and how hamartin participates in this process. We show that hamartin co-localizes with hypophosphorylated tuberin at the membrane, where tuberin exerts its GTPase-activating protein ( GAP) activity to repress Rheb signaling. In response to growth signals, tuberin is phosphorylated by AKT and translocates to the cytosol, relieving Rheb repression. Phosphorylation of tuberin at serines 939 and 981 does not alter its intrinsic GAP activity toward Rheb but partitions tuberin to the cytosol, where it is bound by 14-3-3 proteins. Thus, tuberin bound by 14-3-3 in response to AKT phosphorylation is sequestered away from its membrane-bound activation partner ( hamartin) and its target GTPase (Rheb) to relieve the growth inhibitory effects of this tumor suppressor.
引用
收藏
页码:279 / 289
页数:11
相关论文
共 48 条
[1]   Molecular basis for the substrate specificity of protein kinase B; Comparison with MAPKAP kinase-1 and p70 S6 kinase [J].
Alessi, DR ;
Caudwell, FB ;
Andjelkovic, M ;
Hemmings, BA ;
Cohen, P .
FEBS LETTERS, 1996, 399 (03) :333-338
[2]   Quantitative phosphorylation profiling of the ERK/p90 ribosomal S6 kinase-signaling cassette and its targets, the tuberous sclerosis tumor suppressors [J].
Ballif, BA ;
Roux, PP ;
Gerber, SA ;
MacKeigan, JP ;
Blenis, J ;
Gygi, SP .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (03) :667-672
[3]   The TOR pathway: A target for cancer therapy [J].
Bjornsti, MA ;
Houghton, PJ .
NATURE REVIEWS CANCER, 2004, 4 (05) :335-348
[4]   Molecular genetic advances in tuberous sclerosis [J].
Cheadle, JP ;
Reeve, MP ;
Sampson, JR ;
Kwiatkowski, DJ .
HUMAN GENETICS, 2000, 107 (02) :97-114
[5]  
Clark GJ, 1997, J BIOL CHEM, V272, P10608
[6]   RETRACTED: Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin (Retracted Article) [J].
Dan, HC ;
Sun, M ;
Yang, L ;
Feldman, RI ;
Sui, XM ;
Ou, CC ;
Nellist, M ;
Yeung, RS ;
Halley, DJJ ;
Nicosia, SV ;
Pledger, WJ ;
Cheng, JQ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (38) :35364-35370
[7]   Eicosapentaenoic acid restores tamoxifen sensitivity in breast cancer cells with high Akt activity [J].
deGraffenried, LA ;
Friedrichs, WE ;
Fulcher, L ;
Fernandes, G ;
Silva, JM ;
Peralba, JM ;
Hidalgo, M .
ANNALS OF ONCOLOGY, 2003, 14 (07) :1051-1056
[8]   Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2 [J].
Garami, A ;
Zwartkruis, FJT ;
Nobukuni, T ;
Joaquin, M ;
Roccio, M ;
Stocker, H ;
Kozma, SC ;
Hafen, E ;
Bos, JL ;
Thomas, G .
MOLECULAR CELL, 2003, 11 (06) :1457-1466
[9]  
GOMEZ MR, 1999, DEV PERSPECTIVES PSY, V10, P275
[10]   Tuberous sclerosis gene products in proliferation control [J].
Hengstschläger, M ;
Rodman, DM ;
Miloloza, A ;
Hengstschläger-Ottnad, E ;
Rosner, M ;
Kubista, M .
MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH, 2001, 488 (03) :233-239